Phase 2
Completed N=26
Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer
Source: ClinicalTrials.gov NCT00170625 ↗Enrolled (actual)
26
Serious AEs
46.2%
Results posted
Feb 2017
Primary outcomePrimary: Occurrence of a DLT (Dose Limiting Toxicity) — 0; 1 Participants
Summary
Compatibility of the topotecan therapy in combination with carboplatin.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Occurrence of a DLT (Dose Limiting Toxicity) |
0; 1 | — |
| SECONDARY Progression-free Survival (PFS) |
7.3; 8.4 | — |
Eligibility Criteria
Inclusion Criteria
- Age >= 18 years
- patient with ovarian cancer after primary therapy
- bone marrow function leukocytes >= 4, 0 x 109/ l, platelets >= 100 109/l, hemoglobin >= 9 g/dl
- renal function creatinin = 60 ml/min
- liver function bilirubin 2
- patients with radiotherapy within the last 4 weeks
Data sourced from ClinicalTrials.gov (NCT00170625). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.